Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells

Feng, Panpan; Zhang, Jingru; Zhang, Juan; Liu, Xiaomin; Pan, Lina; Chen, Dawei; Ji, Min; Lu, Fei; Li, Peng; Li, Guosheng; Sun, Tao; Li, Jingxin; Ye, Jingjing; Ji, Chunyan

doi:10.3389/fcell.2022.842214

Download

Article (Scientific journals)

Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells

Feng, Panpan; Zhang, Jingru; Zhang, Juan et al.

2022 • In Frontiers in Cell and Developmental Biology, 10

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/291611

DOI
10.3389/fcell.2022.842214

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

22 Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells.pdf

Author postprint (4 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cell Biology; Developmental Biology

Abstract :

[en] The FLT3-ITD mutation occurs in about 30% of acute myeloid leukemia (AML) and is associated with poor prognosis. However, FLT3 inhibitors are only partially effective and prone to acquired resistance. Here, we identified Yes-associated protein 1 (YAP1) as a tumor suppressor in FLT3-ITD+ AML. YAP1 inactivation conferred FLT3-ITD+ AML cell resistance to chemo- and targeted therapy. Mass spectrometric assay revealed that DNA damage repair gene poly (ADP-ribose) polymerase 1 (PARP1) might be the downstream of YAP1, and the pro-proliferative effect by YAP1 knockdown was partly reversed via PARP1 inhibitor. Importantly, histone deacetylase 10 (HDAC10) contributed to decreased YAP1 acetylation levels through histone H3 lysine 27 (H3K27) acetylation, leading to the reduced nuclear accumulation of YAP1. Selective HDAC10 inhibitor chidamide or HDAC10 knockdown activated YAP1, enhanced DNA damage, and significantly attenuated FLT3-ITD+ AML cell resistance. In addition, combination chidamide with FLT3 inhibitors or chemotherapy agents synergistically inhibited growth and increased apoptosis of FLT3-ITD+ AML cell lines and acquired resistant cells from the relapse FLT3-ITD+ AML patients. These findings demonstrate that the HDAC10-YAP1-PARP1 axis maintains FLT3-ITD+ AML cells and targeting this axis might improve clinical outcomes in FLT3-ITD+ AML patients.

Disciplines :

Hematology

Author, co-author :

Feng, Panpan

Zhang, Jingru

Zhang, Juan

Liu, Xiaomin

Pan, Lina

Chen, Dawei ; Université de Liège - ULiège > GIGA

Ji, Min

Lu, Fei

Li, Peng

Li, Guosheng

More authors (4 more)

Language :

English

Title :

Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells

Publication date :

17 May 2022

Journal title :

Frontiers in Cell and Developmental Biology

eISSN :

2296-634X

Publisher :

Frontiers Media SA

Volume :

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.frontiersin.org/articles/10.3389/fcell.2022.842214/full

Available on ORBi :

since 01 June 2022

Statistics

Number of views

33 (3 by ULiège)

Number of downloads

37 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Avruch J. Zhou D. Bardeesy N. (2012). YAP Oncogene Overexpression Supercharges colon Cancer Proliferation. Cell Cycle 11 (6), 1090–1096. 10.4161/cc.11.6.19453
Bai N. Zhang C. Liang N. Zhang Z. Chang A. Yin J. et al. (2013). Yes-associated Protein (YAP) Increases Chemosensitivity of Hepatocellular Carcinoma Cells by Modulation of P53. Cancer Biol. Ther. 14 (6), 511–520. 10.4161/cbt.24345
Bertini E. Oka T. Sudol M. Strano S. Blandino G. (2009). YAP: at the Crossroad between Transformation and Tumor Suppression. Cell Cycle 8 (1), 49–57. 10.4161/cc.8.1.7259
Caracciolo D. Riillo C. Di Martino M. T. Tagliaferri P. Tassone P. (2021). Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel. Cancers (Basel) 13 (6), 1392. 10.3390/cancers13061392
Cottini F. Hideshima T. Xu C. Sattler M. Dori M. Agnelli L. et al. (2014). Rescue of Hippo Coactivator YAP1 Triggers DNA Damage-Induced Apoptosis in Hematological Cancers. Nat. Med. 20 (6), 599–606. 10.1038/nm.3562
Crisanti M. C. Wallace A. F. Kapoor V. Vandermeers F. Dowling M. L. Pereira L. P. et al. (2009). The HDAC Inhibitor Panobinostat (LBH589) Inhibits Mesothelioma and Lung Cancer Cells In Vitro and In Vivo with Particular Efficacy for Small Cell Lung Cancer. Mol. Cancer Ther. 8 (8), 2221–2231. 10.1158/1535-7163.mct-09-0138
Daver N. Schlenk R. F. Russell N. H. Levis M. J. (2019). Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Leukemia 33 (2), 299–312. 10.1038/s41375-018-0357-9
De Kouchkovsky I. Abdul-Hay M. (2016). Acute Myeloid Leukemia: a Comprehensive Review and 2016 Update. Blood Cancer J. 6 (7), e441. 10.1038/bcj.2016.50
Demchak B. Hull T. Reich M. Liefeld T. Smoot M. Ideker T. et al. (2014). Cytoscape: the Network Visualization Tool for GenomeSpace Workflows. F1000Res 3, 151. 10.12688/f1000research.4492.1
Duvic M. Talpur R. Ni X. Zhang C. Hazarika P. Kelly C. et al. (2007). Phase 2 Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous T-Cell Lymphoma (CTCL). Blood 109 (1), 31–39. 10.1182/blood-2006-06-025999
Hata S. Hirayama J. Kajiho H. Nakagawa K. Hata Y. Katada T. et al. (2012). A Novel Acetylation Cycle of Transcription Co-activator Yes-Associated Protein that Is Downstream of Hippo Pathway Is Triggered in Response to SN2 Alkylating Agents. J. Biol. Chem. 287 (26), 22089–22098. 10.1074/jbc.m111.334714
Huang X. Gao L. Wang S. Lee C.-K. Ordentlich P. Liu B. (2009). HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-Regulation of erbB3 Expression. Cancer Res. 69 (21), 8403–8411. 10.1158/0008-5472.can-09-2146
Kiyoi H. Yanada M. Ozekia K. (2005). Clinical Significance of FLT3 in Leukemia. Int. J. Hematol. 82 (2), 85–92. 10.1532/ijh97.05066
Kowalik M. A. Saliba C. Pibiri M. Perra A. Ledda-Columbano G. M. Sarotto I. et al. (2011). Yes-associated Protein Regulation of Adaptive Liver Enlargement and Hepatocellular Carcinoma Development in Mice. Hepatology 53 (6), 2086–2096. 10.1002/hep.24289
Lahue R. S. Frizzell A. (2012). Histone Deacetylase Complexes as Caretakers of Genome Stability. Epigenetics 7 (8), 806–810. 10.4161/epi.20922
Li H.-J. Fu J.-K. Che X.-M. Fan L. Zhang Y. Bai E. (2017). Obesity Accelerates Murine Gastric Cancer Growth by Modulating the Sirt1/YAP Pathway. Oncol. Lett. 14 (4), 4151–4157. 10.3892/ol.2017.6715
Li H. Huang Z. Gao M. Huang N. Luo Z. Shen H. et al. (2016). Inhibition of YAP Suppresses CML Cell Proliferation and Enhances Efficacy of Imatinib In Vitro and In Vivo. J. Exp. Clin. Cancer Res. 35 (1), 134. 10.1186/s13046-016-0414-z
Li L. Osdal T. Ho Y. Chun S. McDonald T. Agarwal P. et al. (2014). SIRT1 Activation by a C-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. Cell Stem Cell 15 (4), 431–446. 10.1016/j.stem.2014.08.001
Liu Y. Cheney M. D. Gaudet J. J. Chruszcz M. Lukasik S. M. Sugiyama D. et al. (2006). The Tetramer Structure of the Nervy Homology Two Domain, NHR2, Is Critical for AML1/ETO's Activity. Cancer Cell 9 (4), 249–260. 10.1016/j.ccr.2006.03.012
Long J. Jia M.-Y. Fang W.-Y. Chen X.-J. Mu L.-L. Wang Z.-Y. et al. (2020). FLT3 Inhibition Upregulates HDAC8 via FOXO to Inactivate P53 and Promote Maintenance of FLT3-ITD+ Acute Myeloid Leukemia. Blood 135 (17), 1472–1483. 10.1182/blood.2019003538
Lübbert M. Grishina O. Schmoor C. Schlenk R. F. Jost E. Crysandt M. et al. (2020). Valproate and Retinoic Acid in Combination with Decitabine in Elderly Nonfit Patients with Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. Jco 38 (3), 257–270. 10.1200/jco.19.01053
Ma K. Xu Q. Wang S. Zhang W. Liu M. Liang S. et al. (2016). Nuclear Accumulation of Yes-Associated Protein (YAP) Maintains the Survival of Doxorubicin-Induced Senescent Cells by Promoting Survivin Expression. Cancer Lett. 375 (1), 84–91. 10.1016/j.canlet.2016.02.045
Meng Z. Moroishi T. Guan K.-L. (2016). Mechanisms of Hippo Pathway Regulation. Genes Dev. 30 (1), 1–17. 10.1101/gad.274027.115
Moroishi T. Hansen C. G. Guan K.-L. (2015). The Emerging Roles of YAP and TAZ in Cancer. Nat. Rev. Cancer 15 (2), 73–79. 10.1038/nrc3876
Ogawa Y. Ogura M. Tobinai K. Ando K. Suzuki T. Watanabe T. et al. (2016). A Phase I Study of Vorinostat Combined with Bortezomib in Japanese Patients with Relapsed or Refractory Multiple Myeloma. Int. J. Hematol. 103 (1), 25–33. 10.1007/s12185-015-1897-7
Pan D. (2010). The Hippo Signaling Pathway in Development and Cancer. Dev. Cel. 19 (4), 491–505. 10.1016/j.devcel.2010.09.011
Papaemmanuil E. Gerstung M. Bullinger L. Gaidzik V. I. Paschka P. Roberts N. D. et al. (2016). Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374 (23), 2209–2221. 10.1056/nejmoa1516192
Pefani D. E. O'Neill E. (2016). Hippo Pathway and protection of Genome Stability in Response to DNA Damage. FEBS J. 283 (8), 1392–1403. 10.1111/febs.13604
Pobbati A. V. Hong W. (2013). Emerging Roles of TEAD Transcription Factors and its Coactivators in Cancers. Cancer Biol. Ther. 14 (5), 390–398. 10.4161/cbt.23788
San José-Enériz E. Gimenez-Camino N. Agirre X. Prosper F. (2019). HDAC Inhibitors in Acute Myeloid Leukemia. Cancers (Basel) 11 (11), 1794. 10.3390/cancers11111794
Wang C. J. Li D. Danielson J. A. Zhang E. H. Dong Z. Miller K. D. et al. (2021). Proton Pump Inhibitors Suppress DNA Damage Repair and Sensitize Treatment Resistance in Breast Cancer by Targeting Fatty Acid Synthase. Cancer Lett. 509, 1–12. 10.1016/j.canlet.2021.03.026
Wang K. Degerny C. Xu M. Yang X.-J. (2009). YAP, TAZ, and Yorkie: a Conserved Family of Signal-Responsive Transcriptional Coregulators in Animal Development and Human Disease. Biochem. Cel Biol. 87 (1), 77–91. 10.1139/o08-114
Wang L. Cai W. Zhang W. Chen X. Dong W. Tang D. et al. (2015). Inhibition of poly(ADP-Ribose) Polymerase 1 Protects against Acute Myeloid Leukemia by Suppressing the Myeloproliferative Leukemia Virus Oncogene. Oncotarget 6 (29), 27490–27504. 10.18632/oncotarget.4748
West A. C. Johnstone R. W. (2014). New and Emerging HDAC Inhibitors for Cancer Treatment. J. Clin. Invest. 124 (1), 30–39. 10.1172/jci69738
Yu F.-X. Guan K.-L. (2013). The Hippo Pathway: Regulators and Regulations. Genes Dev. 27 (4), 355–371. 10.1101/gad.210773.112
Yu L. L. Dai N. Yu H. G. Sun L. M. Si J. M. (2010). Akt Associates with Nuclear Factor kappaB and Plays an Important Role in Chemoresistance of Gastric Cancer Cells. Oncol. Rep. 24 (1), 113–119. 10.3892/or_00000835
Yuan F. Wang J. Li R. Zhao X. Zhang Y. Liu B. et al. (2019). A New Regulatory Mechanism between P53 and YAP Crosstalk by SIRT1 Mediated Deacetylation to Regulate Cell Cycle and Apoptosis in A549 Cell Lines. Cmar 11, 8619–8633. 10.2147/cmar.s214826
Zhang P. Brinton L. T. Williams K. Sher S. Orwick S. Tzung-Huei L. et al. (2021). Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clin. Cancer Res. 27 (8), 2352–2366. 10.1158/1078-0432.ccr-20-3724
Zhao B. Wei X. Li W. Udan R. S. Yang Q. Kim J. et al. (2007). Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control. Genes Dev. 21 (21), 2747–2761. 10.1101/gad.1602907
Zhou L. Xu N. Shibata H. Saloura V. Uppaluri R. (2021). Epigenetic Modulation of Immunotherapy and Implications in Head and Neck Cancer. Cancer Metastasis Rev. 40 (1), 141–152. 10.1007/s10555-020-09944-0